Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Teladoc Health

DB:4LL
Snowflake Description

Excellent balance sheet with concerning outlook.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4LL
DB
$10B
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. The last earnings update was 42 days ago. More info.


Add to Portfolio Compare Print
  • Teladoc Health has significant price volatility in the past 3 months.
4LL Share Price and Events
7 Day Returns
-14.1%
DB:4LL
16.8%
DE Healthcare Services
2.1%
DE Market
1 Year Returns
159.8%
DB:4LL
15.8%
DE Healthcare Services
-16.6%
DE Market
4LL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Teladoc Health (4LL) -14.1% 13.4% 67.7% 159.8% 457.1% -
DE Healthcare Services 16.8% 4.4% -1.9% 15.8% 50.3% 117%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • 4LL outperformed the Healthcare Services industry which returned 15.8% over the past year.
  • 4LL outperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
4LL
Industry
5yr Volatility vs Market

4LL Value

 Is Teladoc Health undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Teladoc Health to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Teladoc Health.

DB:4LL Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 16 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 4.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:4LL
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.79
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.794 (1 + (1- 21%) (4.56%))
0.881
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.881 * 5.44%)
4.4%

Discounted Cash Flow Calculation for DB:4LL using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Teladoc Health is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:4LL DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 4.4%)
2020 26.52 Analyst x6 25.40
2021 45.46 Analyst x4 41.70
2022 33.38 Analyst x3 29.33
2023 142.68 Analyst x2 120.10
2024 249.69 Analyst x2 201.31
2025 336.92 Est @ 34.93% 260.18
2026 418.92 Est @ 24.34% 309.86
2027 489.79 Est @ 16.92% 347.01
2028 547.23 Est @ 11.73% 371.35
2029 591.51 Est @ 8.09% 384.48
Present value of next 10 years cash flows $2,090.00
DB:4LL DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $591.51 × (1 + -0.39%) ÷ (4.4% – -0.39%)
$12,295.24
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $12,295.24 ÷ (1 + 4.4%)10
$7,991.79
DB:4LL Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,090.00 + $7,991.79
$10,081.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,081.79 / 73.01
$138.09
DB:4LL Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:4LL represents 0.91299x of NYSE:TDOC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.91299x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 138.09 x 0.91299
€126.08
Value per share (EUR) From above. €126.08
Current discount Discount to share price of €128.96
= -1 x (€128.96 - €126.08) / €126.08
-2.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Teladoc Health is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Teladoc Health's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Teladoc Health's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4LL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.38
NYSE:TDOC Share Price ** NYSE (2020-04-07) in USD $141.25
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.51x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Teladoc Health.

DB:4LL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:TDOC Share Price ÷ EPS (both in USD)

= 141.25 ÷ -1.38

-102.65x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Teladoc Health is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • Teladoc Health is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Teladoc Health's expected growth come at a high price?
Raw Data
DB:4LL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -102.65x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts
43.9%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.68x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Teladoc Health, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Teladoc Health's assets?
Raw Data
DB:4LL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $13.94
NYSE:TDOC Share Price * NYSE (2020-04-07) in USD $141.25
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.82x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:4LL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:TDOC Share Price ÷ Book Value per Share (both in USD)

= 141.25 ÷ 13.94

10.14x

* Primary Listing of Teladoc Health.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Teladoc Health is overvalued based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess Teladoc Health's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. Teladoc Health has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4LL Future Performance

 How is Teladoc Health expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
43.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Teladoc Health expected to grow at an attractive rate?
  • Unable to compare Teladoc Health's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Teladoc Health's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Teladoc Health's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:4LL Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:4LL Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 16 Analysts 43.9%
DB:4LL Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 16 Analysts 18.1%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 26.9%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4LL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4LL Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 1,425 1
2023-12-31 1,344 2
2022-12-31 1,088 81 -13 5
2021-12-31 896 64 -50 14
2020-12-31 714 28 -79 16
2020-04-08
DB:4LL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 553 30 -99
2019-09-30 520 14 -105
2019-06-30 493 11 -108
2019-03-31 457 1 -103
2018-12-31 418 -5 -97
2018-09-30 372 -15 -117
2018-06-30 330 -37 -125
2018-03-31 280 -36 -115
2017-12-31 233 -34 -107
2017-09-30 194 -35 -77
2017-06-30 157 -38 -75
2017-03-31 139 -47 -75

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Teladoc Health is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Teladoc Health's revenue is expected to grow by 18.1% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4LL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below

All data from Teladoc Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4LL Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 -0.16 0.59 -0.81 3.00
2021-12-31 -0.71 0.20 -1.05 13.00
2020-12-31 -1.09 -0.16 -1.33 16.00
2020-04-08
DB:4LL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.38
2019-09-30 -1.47
2019-06-30 -1.53
2019-03-31 -1.52
2018-12-31 -1.47
2018-09-30 -1.85
2018-06-30 -2.08
2018-03-31 -1.99
2017-12-31 -1.93
2017-09-30 -1.46
2017-06-30 -1.51
2017-03-31 -1.63

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Teladoc Health is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Teladoc Health's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Teladoc Health has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4LL Past Performance

  How has Teladoc Health performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Teladoc Health's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Teladoc Health does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Teladoc Health's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Teladoc Health's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
Teladoc Health's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Teladoc Health Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4LL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 553.31 -98.86 339.07 64.64
2019-09-30 519.56 -104.70 324.25 61.94
2019-06-30 492.55 -107.62 305.90 59.77
2019-03-31 456.84 -103.37 284.07 57.46
2018-12-31 417.91 -97.08 265.16 54.37
2018-09-30 372.31 -116.59 247.11 51.28
2018-06-30 329.99 -124.65 225.78 47.66
2018-03-31 280.03 -114.99 200.07 40.85
2017-12-31 233.28 -106.78 180.30 34.46
2017-09-30 193.54 -76.66 150.34 29.91
2017-06-30 157.27 -75.10 132.62 25.81
2017-03-31 139.17 -74.57 123.00 23.10
2016-12-31 123.16 -74.22 113.65 21.82
2016-09-30 108.40 -74.96 105.13 20.08
2016-06-30 95.99 -58.44 96.45 18.16
2016-03-31 87.78 -60.62 94.22 16.53
2015-12-31 77.38 -58.02 89.27 14.21
2015-09-30 67.67 -50.01 77.40 12.41
2015-06-30 58.60 -42.29 66.74 10.43
2015-03-31 50.61 -29.48 50.64 9.29
2014-12-31 43.53 -20.13 38.23 7.57
2013-12-31 19.91 -9.84 17.10 3.53

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Teladoc Health has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Teladoc Health has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Teladoc Health improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Teladoc Health's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Teladoc Health has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4LL Health

 How is Teladoc Health's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Teladoc Health's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Teladoc Health is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Teladoc Health's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Teladoc Health's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Teladoc Health Company Filings, last reported 3 months ago.

DB:4LL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,014.03 440.41 517.06
2019-09-30 993.74 433.76 490.88
2019-06-30 1,002.64 427.20 472.60
2019-03-31 1,001.56 420.89 479.70
2018-12-31 1,013.12 414.68 478.53
2018-09-30 1,027.77 408.65 472.53
2018-06-30 699.38 402.76 132.36
2018-03-31 550.87 210.43 119.73
2017-12-31 558.90 207.37 122.31
2017-09-30 446.78 371.33 172.88
2017-06-30 399.38 243.84 440.29
2017-03-31 343.43 42.43 175.95
2016-12-31 230.87 44.42 65.81
2016-09-30 242.30 44.47 74.95
2016-06-30 151.96 31.39 112.48
2016-03-31 165.10 26.21 119.72
2015-12-31 178.56 26.48 137.35
2015-09-30 192.54 27.11 152.00
2015-06-30 39.03 32.66 15.42
2015-03-31 41.37 26.05 32.06
2014-12-31 50.38 25.87 46.44
2013-12-31 16.20 3.00 3.21
  • Teladoc Health's level of debt (43.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (51.5% vs 43.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making Teladoc Health has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making Teladoc Health has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -16.8% per year.
X
Financial health checks
We assess Teladoc Health's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Teladoc Health has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4LL Dividends

 What is Teladoc Health's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Teladoc Health dividends. Estimated to be 0% next year.
If you bought €2,000 of Teladoc Health shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Teladoc Health's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Teladoc Health's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4LL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 16 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:4LL Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 3.00
2020-12-31 0.00 4.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Teladoc Health has not reported any payouts.
  • Unable to verify if Teladoc Health's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Teladoc Health's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Teladoc Health has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Teladoc Health's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Teladoc Health's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Teladoc Health afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Teladoc Health has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4LL Management

 What is the CEO of Teladoc Health's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jason Gorevic
COMPENSATION $7,329,322
AGE 47
TENURE AS CEO 10.8 years
CEO Bio

Mr. Jason N. Gorevic has been Chief Executive Officer at TelaDoc, Inc. (Formerly TelaDoc Medical Services Inc.) since June 2009. Mr. Gorevic serves as Director of Doximity, Inc. since April 2019. Mr. Gorevic served as President at TelaDoc, Inc. since June 2009 until November 1, 2017. He served as Senior Vice President and Chief Sales & Marketing Officer of Anthem, Inc. (formerly WellChoice Inc.), since September 2004. He joined WellPoint Inc. in 2002 and served as its Senior Vice President and Chief Marketing and Product Officer since November 1, 2006. He also served as the President of New York Market of WellPoint Inc. from January 3, 2006 to November 1,2006. He served as the President of Lumenos, Inc. Mr. Gorevic served as Senior Vice President and Chief Sales and Marketing Officer of Empire HealthChoice HMO, Inc. (formerly, Empire HealthChoice, Inc). He served as Chief Marketing Officer of Empire Healthchoice, Inc. since November 2002, Senior Vice President of Local Group Commercial Markets since February 2002 and Acting Head of Sales since July 2003. Mr. Gorevic was also responsible for a provider contracting team that managed approximately 200 hospitals and 80,000 physicians representing $6.5 billion of medical spend. He served as an Acting Head of Sales of WellChoice Inc. since July 2003. Prior thereto, he served as Acting Chief Marketing Officer of WellChoice from November 2002 to February 2003 and served as Vice President of Local Group Commercial Markets of WellChoice from September 2002 to November 2002 and of HealthChoice from February 2002 to November 2002. From July 2000 to December 2001, Mr. Gorevic served as Chief Executive Officer of LuxuryGems, Inc. d/b/a Gemfinity, an electronic marketplace and purchasing aggregator. From July 1999 to July 2000, he served as General Manager of Business Messaging at Mail.com, Inc., a provider of Internet messaging services and from April 1998 to June 1999, he served as Mail.com's Vice President of Operations. From 1993 to 1998, Mr. Gorevic worked at Oxford Health Plans, Inc., and held a variety of positions in marketing, medical management and operations as well as served as Director of Service Strategy. He has been a Director of TelaDoc Inc. since June 2009. While at Oxford Health Plans, he designed, built and managed a first-of-its-kind telephone medical advice service staffed by Registered Nurses to ensure appropriate utilization of health care resources. He is a two-time winner of the WellPoint Pinnacle Award for outstanding leadership and at the age of 31, was named one of the 2003 Crain's New York Business "40 Under 40" top executives. Mr. Gorevic holds a B.A. in International Relations from the University of Pennsylvania.

CEO Compensation
  • Jason's compensation has increased whilst company is loss making.
  • Jason's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Teladoc Health management team in years:

4.6
Average Tenure
50
Average Age
  • The tenure for the Teladoc Health management team is about average.
Management Team

Jason Gorevic

TITLE
CEO & Director
COMPENSATION
$7M
AGE
47
TENURE
10.8 yrs

Peter McClennen

TITLE
President
COMPENSATION
$5M
AGE
50
TENURE
2.4 yrs

Adam Vandervoort

TITLE
Chief Legal Officer & Secretary
COMPENSATION
$2M
AGE
44
TENURE
5.2 yrs

Stephany Verstraete

TITLE
Chief Marketing Officer
COMPENSATION
$2M
AGE
50
TENURE
4.3 yrs

George Brooks

TITLE
Co-Founder
TENURE
18.3 yrs

Mala Murthy

TITLE
Chief Financial Officer
AGE
55
TENURE
0.8 yrs

David Sides

TITLE
Chief Operating Officer
AGE
48
TENURE
0.8 yrs

Gabriel Cappucci

TITLE
Chief Accounting Officer
AGE
56
TENURE
4.9 yrs

Jeff Nadler

TITLE
Chief Information Officer
AGE
55

Patrick Feeley

TITLE
Vice President of Investor Relations
Board of Directors Tenure

Average tenure and age of the Teladoc Health board of directors in years:

5.3
Average Tenure
65.5
Average Age
  • The tenure for the Teladoc Health board of directors is about average.
Board of Directors

Dave Snow

TITLE
Independent Chairman
COMPENSATION
$274K
AGE
64
TENURE
5.3 yrs

Jason Gorevic

TITLE
CEO & Director
COMPENSATION
$7M
AGE
47
TENURE
10.8 yrs

Tom McKinley

TITLE
Independent Director
COMPENSATION
$246K
AGE
67
TENURE
10.4 yrs

Michael Goldstein

TITLE
Independent Director
COMPENSATION
$253K
AGE
77
TENURE
5.2 yrs

David Shedlarz

TITLE
Independent Director
COMPENSATION
$259K
AGE
71
TENURE
3.6 yrs

Arneek Multani

TITLE
Independent Director
COMPENSATION
$249K
AGE
45
TENURE
12.3 yrs

Bill Frist

TITLE
Independent Director
COMPENSATION
$245K
AGE
67
TENURE
5.6 yrs

Helen Darling

TITLE
Independent Director
COMPENSATION
$236K
AGE
77
TENURE
3.8 yrs

Ken Paulus

TITLE
Independent Director
COMPENSATION
$240K
AGE
59
TENURE
3.2 yrs

Brian McAndrews

TITLE
Independent Director
COMPENSATION
$249K
AGE
60
TENURE
2.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Teladoc Health's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Teladoc Health has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4LL News

Simply Wall St News

4LL Company Info

Description

Teladoc Health, Inc. provides virtual healthcare services on a business-to-business basis in the United States and internationally. It covers various clinical conditions, including non-critical, episodic care, chronic, and complicated cases like cancer and congestive heart failure, as well as offers telehealth solutions, expert medical services, behavioral health solutions, guidance and support, and platform and program services. The company’s platform enables patients and providers to have an integrated smart user experience through mobile, Web, and phone based accessed points. 0It serves health employers, health plans, hospitals, health systems, and insurance and financial services companies. Teladoc Health, Inc. offers its products and services under the Teladoc, Advance Medical, Best Doctors, BetterHelp, and HealthiestYou brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.

Details
Name: Teladoc Health, Inc.
4LL
Exchange: DB
Founded: 2002
$9,468,867,781
73,008,312
Website: http://www.teladochealth.com
Address: Teladoc Health, Inc.
2 Manhattanville Road,
Suite 203,
Purchase,
New York, 10577,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE TDOC Common Stock New York Stock Exchange US USD 01. Jul 2015
DB 4LL Common Stock Deutsche Boerse AG DE EUR 01. Jul 2015
LSE 0LDR Common Stock London Stock Exchange GB USD 01. Jul 2015
BRSE 4LL Common Stock Berne Stock Exchange CH CHF 01. Jul 2015
BMV TDOC * Common Stock Bolsa Mexicana de Valores MX MXN 01. Jul 2015
Number of employees
Current staff
Staff numbers
2,400
Teladoc Health employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 00:58
End of day share price update: 2020/04/07 00:00
Last estimates confirmation: 2020/04/07
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.